Every generic drug manufacturer strives to be the first to produce, register and launch a generic drug on the market. JGL managed to do just that in 2010, when the company launched the first generic version of latanoprost – the Latanox eye drops. It was a turning point for our business, after which we focused our efforts on technologies for producing sterile drops, and on treating the senses in the therapy segment.
It has been a decade since then, and in the meantime, JGL brought its vision of specialising in ophthalmology to life. It has launched an impressive portfolio of ophthalmology products, and continues to improve on the skills of its employees and on technological innovations in R&D and manufacturing in this therapeutic class. We produce Latanox in compliance with the highest European and global quality standards, not only on the local market, but many other JGL markets as well, along with other European markets where we have licence and/or manufacturing agreements. We are proud of our 2020 production plan that includes over 3.5 million bottles, and of the fact that over 290,000 patients use latanoprost produced by JGL every day.
Our very own latanoprost is one of the most commonly prescribed antiglaucoma agents in the world, a true “gold standard” for prostaglandin analogues used to reduce intraocular pressure in patients with ocular hypertension and open-angle glaucoma. In the coming period, we will be celebrating the special, 10-year anniversary of Latanox with all of our customers and patients. The ophthalmology unit of the Zagreb County Community Health Centre were the first to congratulate us on reaching this milestone. The first of many, hopefully!